Amgen and Daiichi Sankyo Announce Agreement for Denosumab in Japan Read more about Amgen and Daiichi Sankyo Announce Agreement for Denosumab in Japan
Amgen Announces Webcast of 2007 Second Quarter Financial Results Read more about Amgen Announces Webcast of 2007 Second Quarter Financial Results
Ralph Lauren Center for Cancer Care and Prevention Receives $2.5 Million from the Amgen Foundation to Launch National Patient Navigation Training Institute Read more about Ralph Lauren Center for Cancer Care and Prevention Receives $2.5 Million from the Amgen Foundation to Launch National Patient Navigation Training Institute
ENBREL Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR Read more about ENBREL Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
Amgen Submits Comments in Response to CMS' Proposed National Coverage Decision Read more about Amgen Submits Comments in Response to CMS' Proposed National Coverage Decision
Amgen to Acquire Alantos Pharmaceuticals, a Private Biotechnology Company in Cambridge, Massachusetts Read more about Amgen to Acquire Alantos Pharmaceuticals, a Private Biotechnology Company in Cambridge, Massachusetts
Amgen to Acquire Ilypsa, a Private San Francisco Bay Area Biotechnology Company Focused on Kidney Disease Care Read more about Amgen to Acquire Ilypsa, a Private San Francisco Bay Area Biotechnology Company Focused on Kidney Disease Care
Amgen Oncology Highlights Upcoming Data Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting Read more about Amgen Oncology Highlights Upcoming Data Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
Amgen to Appeal CHMP Opinion on Vectibix(TM) (Panitumumab) Read more about Amgen to Appeal CHMP Opinion on Vectibix(TM) (Panitumumab)
Amgen Prices $4 Billion of Senior Notes in Three Series; Company to Purchase Approximately $3 Billion in Common Stock Read more about Amgen Prices $4 Billion of Senior Notes in Three Series; Company to Purchase Approximately $3 Billion in Common Stock
